AI assistant
STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2019
Feb 13, 2019
62616_rns_2019-02-13_5ec27167-c432-4d9a-bed6-52e419862b3c.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
February 13, 2019
BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001
Scrip code: 532531
The National Stock Exchange of India Limited Exchange Plaza , Bandra‐Kurla Complex Bandra (E) Mumbai ‐ 400 051
Scrip code: STAR
Dear Sirs,
Sub: Press Release
Please find attached press release issued by the Company titled:
“Strides receives USFDA approval for Triamcinolone Acetonide Cream”
Thanks and Regards
For Strides Pharma Science Limited
==> picture [128 x 52] intentionally omitted <==
Manjula Ramamurthy Company Secretary
==> picture [85 x 83] intentionally omitted <==
Strides Pharma Science Limited
(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 [email protected]; www.strides.com
Press Release February 13, 2019
Strides receives USFDA approval for Triamcinolone Acetonide Cream
Product approval from flagship facility in Bangalore To be marketed by Strides Pharma Inc. in the US market
Bangalore, 13 February, 2019 Strides Pharma Science Limited (Strides) today announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. from the United States Food & Drug Administration (US FDA). The product is a generic version of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc.
According to IQVIA MAT data, the US market for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. is approximately US$ 55 Mn. The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market.
The company has 86 cumulative ANDA filings with USFDA of which 56 ANDAs have been approved including 12 approvals received in FY 19.
About Triamcinolone Acetonide Cream
Triamcinolone Acetonide Cream is used to treat a variety of skin conditions including treatment of eczema, dermatitis, allergies, rash and helps in reducing swelling, itching, and redness that can occur in these types of conditions.
About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor‐funded markets. The Company’s global manufacturing sites are located in India‐ Bangalore (two sites), Pondicherry, and Chennai, Singapore, Italy‐ Milan, and Kenya‐ Nairobi. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com
For further information, please contact:
| StridesBadree Komandur,Executive Director ‐ Finance+91 80 6784 0747 | PR ConsultancyFortuna PRK Srinivas Reddy: +91 90005 27213[email protected] |
|---|
Investor Relations: K Priya: +91 95354 25418 Kannan. N: +91 98450 54745 [email protected] Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791 Email: [email protected] Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN : L24230MH1990PLC057062 Regd. Office: 201, ‘Devavrata’, Sector ‐ 17, Vashi, Navi Mumbai ‐ 400 703 Corp. Office: Strides House, Bannerghatta Road, Bangalore ‐ 560076